A common side effect of stress and trauma in critically ill patients is a rapid increase in blood glucose levels. As with diabetes, the levels can be reduced and controlled by the infusion of insulin. But glucose levels peak and change much more quickly in the ICU environment and there is little room for trial and error. If the situation is not normalised, then complications and even deaths can and do occur.
Twice in the past, Europe-wide studies and trials were put in place to try and come up with a solution to the problem. But in both cases they were prematurely halted because researchers could not solve the problem of overcompensating and patients developing hypoglycaemia, or abnormally low blood sugar levels.
“What these studies did clearly indicate is that the establishment of normal glucose levels in critically ill patients is very difficult to achieve without some sort of automated system to help the nurses,” says Dr Martin Ellmerer, scientific coordinator of the CLINICIP project which has developed just such a system.Nurses’ no-nonsense approach
Partners in this EU-funded project, academic medical institutions plus one private-sector medical equipment manufacturer, decided they needed to develop a two-step approach. “We first developed a decision-support system which met all the criteria outlined by the ICU staff, and later developed a fully automated system,” he tells ICT Results.
At the heart of both systems is a sophisticated bit of computer software (an algorithm) written especially for this project.
With the decision-support system, nurses still have to draw blood from patients in the traditional way and test it for glucose levels. They enter the information via the user interface – a touch screen – the researchers have developed. The algorithm takes over at this stage, calculates how much insulin is needed and automatically administers it. It also alerts the nurse when a new blood sample needs to be taken and analysed – half an hour in the worst cases and up to four hours in less severe cases.
“We have fully functioning prototypes of the decision-support system which we successfully trialled in ICUs at different hospitals around Europe,” Ellmerer says. The project’s industrial partner, B. Braun Melsungen AG, is ready to go into commercial production of the system working together with the clinical partners.
“We will first have to go through an approval process and the systems should be commercially available to hospitals in mid-2009,” Ellmerer says. B. Braun is one of the leading manufacturers of infusion systems used in hospitals, and the CLINICIP technology will be incorporated into these as it was during the trials.Developing the real deal
The drawback of this is that a dedicated needle is necessary. “Unfortunately, this is unavoidable for a fully automated system,” Ellmerer points out. Using fibre-optic technology the needle draws blood, sends it for analysis and then returns it to the patient’s vein as well as administering the necessary dose of insulin.
“We have performed a proof-of-concept study to show we are able to establish glucose control in a clinical setting,” Ellmerer says.
To develop the sensor technology further and then commercialise it, a spin-off company will be set up with Ellmerer as CEO and one of the shareholders. The other shareholders are individuals from project partners in CLINICIP. The spin-off will work closely with B. Braun and the partners, although they are not stakeholders in it.
Ellmerer expects the fully automated two-step system to be commercially available in 2011.
“Our research and the products which result from it should have a pretty fundamental impact on ICUs,” he says. “They should improve survival chances, reduce complications, such as sepsis and organ failure, and reduce the time patients need to spend in ICUs.”
Ahmed ElAmin | alfa
Putting food-safety detection in the hands of consumers
15.11.2018 | Massachusetts Institute of Technology
Next stop Morocco: EU partners test innovative space robotics technologies in the Sahara desert
09.11.2018 | Deutsches Forschungszentrum für Künstliche Intelligenz GmbH, DFKI
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
16.11.2018 | Health and Medicine
16.11.2018 | Life Sciences
16.11.2018 | Life Sciences